Large animals like whales and elephants have evolved superior DNA repair and cancer suppression mechanisms, offering insights for human aging and disease prevention. New studies reveal how massive mam...
A 2023 study in the Journal of Cachexia, Sarcopenia and Muscle finds rapamycin reduces muscle protein synthesis after exercise in older adults, highlighting trade-offs in longevity strategies. Recent ...
Life Biosciences launches a Phase I trial for cellular reprogramming to treat age-related macular degeneration, challenging aging norms with FDA’s Plausible Mechanism Pathway, amid rising invest...
Exploring how mild mitochondrial stress through drugs like terbinafine and miglustat extends lifespan, with socioeconomic implications for longevity treatments. New research shows FDA-approved drugs c...
A new study on HMGB1’s Box A domain shows it can create DNA gaps, reversing age-related damage in non-human primates with up to 40% proteomic improvement, highlighting potential gene therapy for...
Recent studies show that FDA-approved antiretroviral FTC/TAF may slow aging by reducing retrotransposon activity, highlighting a promising gerotherapeutic approach with broad accessibility. Groundbrea...
Emerging studies show that aligning meals with circadian rhythms can reduce aging markers in organs like the heart and liver, offering practical strategies for longevity. Recent findings highlight how...
The FDA’s updated guidelines on cellular reprogramming, highlighted by Life Biosciences’ ER-100 trial for eye conditions, signal a pivotal shift that could accelerate anti-aging therapies,...
Analyzing recent rapamycin clinical trials for anti-aging, focusing on optimal dosing, safety, and the shift from off-label use to evidence-based protocols in longevity research. New human trials on r...
A landmark collaboration between Insilico Medicine and Eli Lilly leverages AI to accelerate drug discovery for aging-related diseases, with recent data showing reduced costs and faster development. Th...
